IRadimed Corporation (IRMD) on Decifer

Decifer ranks IRMD number 232 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 21% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 14% a year, profits grew 16% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• It trades about 33% above similar companies, and its growth does not yet back up that price.
• Returns around 21% and steady margins are strong, but no funded role, an unclear read on management, and momentum of 4 out of 35 keep it modest.

The current read

The evidence on IRMD lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Robotic & Minimally-Invasive Intervention: Clinical and economic evidence favoring minimally invasive robotic and thrombectomy procedures is shifting procedure volumes and capital equipment budgets toward advanced interventional platforms.

Read the full IRMD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.